Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly’s Sarcoma Drug Lartruvo Latest To Test EU Conditional Approval System

Executive Summary

Lartruvo, Lilly’s new drug for the rare condition soft tissue sarcoma, has been recommended for conditional marketing authorization in the EU pending the results of an ongoing Phase III study. The conditional approval system itself is under scrutiny regarding the fulfilment of obligations.


Related Content

Lilly's Sarcoma Drug Likely To Be Used Widely Despite EU Conditional OK
Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas
'Skyrocketing' Drug Prices, Access And Availability In Line For EU Scrutiny
EU Conditional Approval Should Be A Drug Development Tool, Not A Rescue Remedy


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts